CLOSING IN ON A CURE

2015 ANNUAL REPORT
OF ALL THE DRUG DISCOVERY PROGRAMS NOW IN CLINICAL TRIALS WE’VE SUPPORTED MORE THAN 20%

Effective treatments for Alzheimer’s are now just years, rather than decades, from becoming a reality. The Alzheimer’s Drug Discovery Foundation is proud to have contributed to over 20% of the drugs now in clinical trials. Over 15 years ago, we seed funded drug discovery by Frank M. Longo, MD, PhD, featured on the cover. And we continued that support, helping him found the biopharmaceutical company PharmatrophiX and develop his drug, LM11A-31. Earlier this year, that drug, which is about to begin Phase 2a clinical trials, was featured on the cover of *Time* magazine and called a potential “game changer.” Read more about his work on page 7.

*Photo credit (cover and page 7): Norbert von der Groeben*
Dear Friends,

At our Fall Symposium & Luncheon in November, we stated an ambitious goal—to be able to treat Alzheimer’s within our lifetimes. Thanks to the Alzheimer’s Drug Discovery Foundation (ADDF), the scientists we fund, and supporters like you, we can and will get there.

By any measure, 2015 was the most successful year in the ADDF’s history. We raised over $22.5 million, more than doubling our fundraising total from 2014. And 100% of donations fund drug discovery programs.

Because of your tremendous support, we are able to invest in even more promising drug programs. And many more of these programs are in human clinical trials—the final stages of development.

We are nearing the finish line. Together we will conquer Alzheimer’s disease.

With our deepest thanks,
INNOVATIVE PROGRAMS
The ADDF bridges a critical gap in research funding—often called “the valley of death”—between basic research supported by government and traditional philanthropy and late-stage clinical trials funded by venture capitalists and pharmaceutical companies. The ADDF's funding ensures innovative ideas for drugs to treat Alzheimer’s get a chance.

BIOTECHS
The ADDF is a pioneer in biomedical venture philanthropy. We fund scientists in both academia and the biopharmaceutical industry. Through the ADDF Biotechnology Founders program, we help researchers create new companies to further their drug development efforts.

CLINICAL RESEARCH
With many of our early investments and repurposing studies now in clinical trials—the final stages of drug development—the ADDF is allocating a larger portion of our funding to programs with the potential to reach patients within the next five years.

ADDF’S STRATEGY: BRIDGING THE GAP
Dear Friends,

Over the course of my 35-year career as both a physician and a scientist, I’ve seen the toll that Alzheimer’s disease takes on patients and their families. The ADDF was founded to end that unnecessary suffering, and we are getting closer than ever to fulfilling our goal.

I’m proud to say that with your support, the ADDF has become a world leader in Alzheimer’s drug discovery. Our funded scientists are translating new findings about the causes of Alzheimer’s disease into drugs to prevent and treat it.

Today, there are over 100 treatments for Alzheimer’s in clinical trials—the last stages of development before a drug is approved for patients. The ADDF has helped support more than 20% of them. Without our funding, promising treatments from biopharmaceutical companies such as PharmatrophiX and Oryzon Genomics—which is developing the very first epigenetic treatment for Alzheimer’s—would not have made it this far. And we’re not resting on our laurels.

In 2015, we invested nearly $13 million in drug discovery programs, the most in our history. We’re directing more of those investments toward clinical trials because the drugs we picked early on have proven to be among the best candidates for a breakthrough.

The ADDF is inspired by the remarkable progress made by drug discovery researchers and proud of the role we’ve played in advancing the field, but we know there’s still work to be done. That’s why we will continue to fund the best ideas in the world for treating Alzheimer’s.

It is a true privilege to work with the ADDF’s committed donors and partners to overcome Alzheimer’s disease. With your continued support, I know we will succeed.

Sincerely,

Howard Fillit, MD
Founding Executive Director and Chief Science Officer
ACCELERATING PROGRESS

In 2015, the Alzheimer’s Drug Discovery Foundation made significant progress toward our goal of finding effective treatments for Alzheimer’s disease. Our strategy is simple. Led by a team of neuroscientists, the ADDF invests in a diverse portfolio of the best ideas to conquer Alzheimer’s.

SEED FUNDING
NOVEL PROGRAMS
We fund scientists as they discover and then develop new ways to prevent and treat Alzheimer’s and related dementias. During 2015, we funded 27 such early-stage programs, including scientists working on revolutionary gene therapy and epigenetic treatments.

INVESTING IN BIOTECHS
Often, researchers developing novel drug programs spin off biotechnology companies as they move toward clinical trials. This can aid in establishing intellectual property and partnerships and in attracting investors. In 2015, we funded 8 new biotechs, including 3 that we helped create through the ADDF Biotechnology Founders Program.

SUPPORTING
CLINICAL TRIALS
Many of our investments—including early funding for programs targeting inflammation—have moved through the drug pipeline and are now in clinical trials. We continue to support these as well as trials for drugs approved for other conditions that show promise for treating Alzheimer’s—a process called “repurposing.” In 2015, we supported 8 new programs in clinical trials, which included 6 repurposing programs.

FORGING PARTNERSHIPS
Developing drugs requires a diverse array of skills and significant time and money. Since our earliest days, the ADDF has partnered with like-minded organizations to leverage our combined resources and provide grantees with the expertise they need. We were proud to be working with 8 partners in 2015.

PROVIDING RESOURCES
The ADDF works to expand the number of scientists in drug discovery and support those already in the field. Our resources include the ACCESS website, which connects researchers with high-quality contract research organizations, as well as annual conferences and courses. At CognitiveVitality.org, we empower the public to make informed decisions about brain health by evaluating various strategies.
Early-stage drug discovery is challenging. It involves a high degree of risk and requires a nuanced understanding of the latest research into the causes of Alzheimer’s. Every new finding about the mechanisms of the disease is also an opportunity to try to prevent or treat it.

Scientists have identified genes that increase risk for Alzheimer’s, such as APOE4, and others that decrease risk. Gene therapy tries to alter genes for the better. Epigenetics—an emerging area for drug discovery—is different. Rather than trying to change actual genes, epigenetics changes how, and how much, those genes are expressed. Think of it like a dimmer switch: you can turn genes on and off and also increase or decrease their intensity.

The ADDF is funding several biotechnology companies trying to “adjust the dimmer” on genes that enhance learning and memory and may slow down the progression of Alzheimer’s disease. In 2015, we made our second investment in Oryzon Genomics, a biotech based in Barcelona, Spain, that we initially funded in 2010. Dr. Tamara Maes and her colleagues at Oryzon are developing ORY-2001, which may become the first epigenetic treatment for Alzheimer’s. Oryzon recently initiated a Phase 1 study of ORY-2001 in healthy subjects, which should lay the groundwork for a planned Phase 2 study in Alzheimer’s patients in 2017. In 2015, the ADDF also made a second grant to the team at Rodin Therapeutics in Cambridge, Massachusetts, which is developing an epigenetic treatment targeting a different set of genes.
INVESTING IN BIOTECHS

Spotlight on Klogene Therapeutics

Founding a biotechnology company can be a difficult but important step for scientists who are developing novel drugs. As drugs move toward clinical trials, the scientists developing them face intellectual property questions and require significant financial backing. The ADDF created the Biotechnology Founders Program to help academic scientists meet these challenges.

In 2015, our grantee Carmela Abraham, PhD, a professor at Boston University School of Medicine, founded Klogene Therapeutics, the 10th company created through the ADDF’s program. With five years of previous support from the ADDF, she developed compounds that boost Klotho, a protein that she found is low in the brains of people with Alzheimer’s disease and multiple sclerosis. Studies have also shown that mice with higher levels of Klotho live up to 30 percent longer than normal mice and have better memory.

Dr. Abraham is currently gearing up to conduct preclinical tests of her Klotho-enhancing compounds and plans to develop the most promising candidates into oral drugs for testing in human clinical trials.
SUPPORTING CLINICAL TRIALS

Spotlight on LM11A-31

Human clinical trials are the final stages of drug development. Here, scientists determine the safest dose of their compound and whether and how it is effective, first in small groups and then in very large trials with thousands of participants.

Many drugs that have been tested for Alzheimer’s targeted amyloid plaques. But in the last few years, the treatments reaching clinical trials for Alzheimer’s disease have had new, more diverse targets, such as inflammation and neuroprotection (i.e., keeping neurons from being injured or dying). The ADDF has helped fund over 20 percent of the treatments now in clinical trials, which includes novel programs we seed-funded over a decade ago.

One of the most promising drugs in clinical trials is LM11A-31, developed by Frank Longo, MD, PhD, and his colleagues. The ADDF funded the earliest stages of Dr. Longo’s drug discovery work in 2000, and since then has awarded him over $2 million to continue development. The resulting drug, LM11A-31, counteracts abnormal signals in the brain that lead to the accumulation of toxic forms of the tau protein and to the degeneration of neurons and their synaptic connections. Inhibiting these processes prevents memory loss and other cognitive issues that occur in Alzheimer’s disease. A Phase 2a trial of LM11A-31, which the ADDF helped fund, is scheduled to begin in summer 2016 at sites in Europe.

For his groundbreaking work, Dr. Longo was chosen by an independent selection committee as the winner of our inaugural Melvin R. Goodes Prize for Excellence in Alzheimer’s Drug Discovery in 2015.
The ADDF has established numerous partnerships to bring additional funding and expertise to our grantees. Our partners include nonprofit organizations, government agencies, pharmaceutical companies, venture funds, and others who are working to accelerate drug discovery. As you’d expect, developing a novel drug requires a team with diverse scientific skills—including neurobiology, medicinal chemistry, pharmacology, and toxicology. But to be successful, the team will also need experience in patent law, business development, commercialization, and marketing—skills more associated with a MBA than a PhD.

To help grantees access the expertise they need to find success, we began a partnership with the Harrington Discovery Institute at University Hospitals in Cleveland, Ohio, in 2013. To advance their research, investigators funded through the partnership receive help from Harrington’s Innovation Support Center in drug discovery project management, regulatory processes, intellectual property, and business development.

In 2015, Carol Colton, PhD, and her colleague James Burke, MD, PhD, received funding through the ADDF-Harrington partnership for preclinical studies on difluoromethylornithine (DFMO), a drug currently being investigated in human clinical trials to treat cancer. The investigators have found that DFMO blocks an immune response in the brain that diminishes arginine, a vital nutrient. Blocking this response prevents the death of neurons and associated memory loss found in Alzheimer’s disease.
Providing Resources

An important part of our mission is providing researchers with the resources they need for drug discovery and development. The ADDF is also committed to providing unbiased information to the public about options to improve brain health and possibly prevent dementia.

Conferences

In 2015, the Alzheimer’s Drug Discovery Foundation organized our 9th Drug Discovery for Neurodegeneration Conference to train researchers in the process of drug discovery and development. And we convened those already working in the field at our 16th International Conference on Alzheimer’s Drug Discovery to share findings, network, and forge partnerships. We also held two meetings that brought together researchers working on Alzheimer’s with others working on cancer, diabetes, and heart disease to help each community learn from the others. AlzDiscovery.org/events

Access

The ACCESS website advanced our mission in 2015 by adding more vendors and resources. ACCESS connects scientists with high-quality contract research organizations (CRO), online project management tools, and educational resources. ADDFaccess.ondeckbiotech.com

Cognitive Vitality

The neuroscientists in our Aging and Alzheimer’s Disease Prevention program evaluate current strategies to promote brain health and prevent dementia and make their findings available to the public at CognitiveVitality.org. In 2015, they shared 18 new reports and 26 blog articles on topics ranging from the risks of concussions and surgery to evaluations of the potential benefits of vinpocetine and astragalus.
NEW AND ONGOING ADDF GRANTS IN 2015

APOE
Ronald Crystal, MD
Weill Cornell Medical College
$1,000,000

EPIGENETICS
Martin Jefson, PhD
Rodin Therapeutics
$161,759

Bradley Hyman, MD, PhD
Harvard Medical School
$250,000

Tamara Maes, PhD
Oryzon Genomics, S.A., Spain
$270,000

COGNITIVE ENHANCERS & SYMPTOM MODIFIERS
Giacomo Koch, MD, PhD
Santa Lucia Foundation, Italy
$250,000

Pavel Petukhov, PhD
University of Illinois at Chicago
$142,100

Krista Lanctôt, PhD
Sunnybrook Research Institute, University of Toronto, Canada
$219,286

Xiang (Simon) Wang, PhD
Howard University College of Pharmacy
$110,000

Allan Levey, MD, PhD
Emory University School of Medicine
$447,900

FRONTOTEMPORAL DEGENERATION
Nigel Cairns, PhD
Washington University in St. Louis
$156,990

Jerri Rook, PhD
Vanderbilt Center of Neuroscience Drug Discovery
$150,000

Matthew Disney, PhD
The Scripps Research Institute
$150,000

Edward Huey, MD
Columbia University
$263,829

Donald Lo, PhD
Duke University Medical Center
$149,603

Scott Sneddon, PhD
Sharp Edge Labs, Inc.
$188,800

NEUROIMAGING AND BIOMARKERS
Adam Boxer, MD, PhD
University of California, San Francisco
$75,000

Mari DeMarco, PhD, DABCC
University of British Columbia, Canada
$164,990

Els Fieremans, PhD
New York University School of Medicine
$200,184

Steven Estus, PhD
University of Kentucky
$177,000

Massimo Filippi, MD
La Fondazione Centro San Raffaele del Monte Tabor, Italy
$125,000

We are supporting over 87 SCIENTISTS GLOBALLY

With $27 million in new and ongoing grant funding
<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sam Gandy, MD, PhD</td>
<td>Icahn School of Medicine at Mount Sinai</td>
<td>$399,822</td>
</tr>
<tr>
<td>Lawrence Honig, MD, PhD</td>
<td>Columbia University</td>
<td>$125,000</td>
</tr>
<tr>
<td>Jacob Hooker, PhD</td>
<td>Massachusetts General Hospital</td>
<td>$400,000</td>
</tr>
<tr>
<td>Daniel Javitt, MD, PhD</td>
<td>Columbia University Medical Center</td>
<td>$300,000</td>
</tr>
<tr>
<td>Ashish Raj, PhD</td>
<td>BrainWire LLC</td>
<td>$275,400</td>
</tr>
<tr>
<td>Blaine Roberts, PhD</td>
<td>The Florey Institute of Neuroscience and Mental Health, Australia</td>
<td>$140,000</td>
</tr>
<tr>
<td>Charlotte Teunissen, PhD</td>
<td>VU University Medical Center, Netherlands</td>
<td>$150,000</td>
</tr>
<tr>
<td>Neil Vasdev, PhD</td>
<td>Massachusetts General Hospital</td>
<td>$331,805</td>
</tr>
<tr>
<td>Peter Working, PhD</td>
<td>Alzeca Biosciences, LLC</td>
<td>$322,111</td>
</tr>
<tr>
<td>Ying Wu, MD</td>
<td>NorthShore University HealthSystem</td>
<td>$85,300</td>
</tr>
<tr>
<td>Carol Colton, PhD</td>
<td>Duke University Medical Center</td>
<td>$155,051</td>
</tr>
<tr>
<td>Luca Ferraro, PharmD</td>
<td>University of Ferrara, Italy</td>
<td>$61,400</td>
</tr>
<tr>
<td>Joseph Foss, MD</td>
<td>NeuroTherapia, Inc.</td>
<td>$1,600,000</td>
</tr>
<tr>
<td>Thota Ganesh, PhD</td>
<td>Emory University</td>
<td>$136,082</td>
</tr>
<tr>
<td>Milton Greenberg, PhD</td>
<td>Vivreon Biosciences, LLC</td>
<td>$150,000</td>
</tr>
<tr>
<td>Gilles Guillemin, PhD</td>
<td>Macquarie University, Australia</td>
<td>$145,157</td>
</tr>
<tr>
<td>Philip Haydon, PhD</td>
<td>GliaCure, Inc.</td>
<td>$1,000,000</td>
</tr>
<tr>
<td>Clive Holmes, PhD</td>
<td>University of Southampton, UK</td>
<td>$533,330</td>
</tr>
<tr>
<td>Alexandros Makriyannis, PhD</td>
<td>Northeastern University</td>
<td>$175,000</td>
</tr>
<tr>
<td>Mohamed Naguib, MB, BCh, MSc, FCARCSI, MD</td>
<td>Cleveland Clinic Foundation</td>
<td>$257,700</td>
</tr>
<tr>
<td>Paolo Pevarello, PhD</td>
<td>Axxam SpA, Italy</td>
<td>$350,000</td>
</tr>
<tr>
<td>Thadd Reeder, PhD</td>
<td>Glialogix, Inc.</td>
<td>$207,000</td>
</tr>
<tr>
<td>John Schetz, PhD</td>
<td>University of North Texas Health Science Center</td>
<td>$216,000</td>
</tr>
<tr>
<td>Malu Tansey, PhD</td>
<td>Emory University School of Medicine</td>
<td>$100,000</td>
</tr>
<tr>
<td>Paul Thompson, PhD</td>
<td>University of Massachusetts Lowell</td>
<td>$150,000</td>
</tr>
<tr>
<td>Linda Van Eldik, PhD</td>
<td>University of Kentucky</td>
<td>$209,364</td>
</tr>
<tr>
<td>Shijun Zhang, PhD</td>
<td>Virginia Commonwealth University</td>
<td>$160,000</td>
</tr>
<tr>
<td>Danna Zimmer, PhD</td>
<td>University of Maryland School of Medicine</td>
<td>$150,000</td>
</tr>
<tr>
<td>James Bennett, MD, PhD</td>
<td>Virginia Commonwealth University</td>
<td>$200,000</td>
</tr>
<tr>
<td>Paul Edison, MD, MRCP, PhD, FRCPI</td>
<td>Imperial College London, UK</td>
<td>$458,000</td>
</tr>
<tr>
<td>Gary Gibson, PhD</td>
<td>Burke Medical Research Institute</td>
<td>$500,000</td>
</tr>
<tr>
<td>Thadd Reeder, PhD</td>
<td>Glialogix, Inc.</td>
<td>$207,000</td>
</tr>
<tr>
<td>John Schetz, PhD</td>
<td>University of North Texas Health Science Center</td>
<td>$216,000</td>
</tr>
<tr>
<td>Malu Tansey, PhD</td>
<td>Emory University School of Medicine</td>
<td>$100,000</td>
</tr>
<tr>
<td>Paul Thompson, PhD</td>
<td>University of Massachusetts Lowell</td>
<td>$150,000</td>
</tr>
<tr>
<td>Linda Van Eldik, PhD</td>
<td>University of Kentucky</td>
<td>$209,364</td>
</tr>
<tr>
<td>Shijun Zhang, PhD</td>
<td>Virginia Commonwealth University</td>
<td>$160,000</td>
</tr>
<tr>
<td>Danna Zimmer, PhD</td>
<td>University of Maryland School of Medicine</td>
<td>$150,000</td>
</tr>
<tr>
<td>James Bennett, MD, PhD</td>
<td>Virginia Commonwealth University</td>
<td>$200,000</td>
</tr>
<tr>
<td>Paul Edison, MD, MRCP, PhD, FRCPI</td>
<td>Imperial College London, UK</td>
<td>$458,000</td>
</tr>
<tr>
<td>Gary Gibson, PhD</td>
<td>Burke Medical Research Institute</td>
<td>$500,000</td>
</tr>
<tr>
<td>Thadd Reeder, PhD</td>
<td>Glialogix, Inc.</td>
<td>$207,000</td>
</tr>
<tr>
<td>John Schetz, PhD</td>
<td>University of North Texas Health Science Center</td>
<td>$216,000</td>
</tr>
<tr>
<td>Malu Tansey, PhD</td>
<td>Emory University School of Medicine</td>
<td>$100,000</td>
</tr>
<tr>
<td>Paul Thompson, PhD</td>
<td>University of Massachusetts Lowell</td>
<td>$150,000</td>
</tr>
<tr>
<td>Linda Van Eldik, PhD</td>
<td>University of Kentucky</td>
<td>$209,364</td>
</tr>
<tr>
<td>Shijun Zhang, PhD</td>
<td>Virginia Commonwealth University</td>
<td>$160,000</td>
</tr>
<tr>
<td>Danna Zimmer, PhD</td>
<td>University of Maryland School of Medicine</td>
<td>$150,000</td>
</tr>
<tr>
<td>James Bennett, MD, PhD</td>
<td>Virginia Commonwealth University</td>
<td>$200,000</td>
</tr>
<tr>
<td>Paul Edison, MD, MRCP, PhD, FRCPI</td>
<td>Imperial College London, UK</td>
<td>$458,000</td>
</tr>
<tr>
<td>Gary Gibson, PhD</td>
<td>Burke Medical Research Institute</td>
<td>$500,000</td>
</tr>
<tr>
<td>Thadd Reeder, PhD</td>
<td>Glialogix, Inc.</td>
<td>$207,000</td>
</tr>
<tr>
<td>John Schetz, PhD</td>
<td>University of North Texas Health Science Center</td>
<td>$216,000</td>
</tr>
<tr>
<td>Malu Tansey, PhD</td>
<td>Emory University School of Medicine</td>
<td>$100,000</td>
</tr>
<tr>
<td>Paul Thompson, PhD</td>
<td>University of Massachusetts Lowell</td>
<td>$150,000</td>
</tr>
<tr>
<td>Linda Van Eldik, PhD</td>
<td>University of Kentucky</td>
<td>$209,364</td>
</tr>
</tbody>
</table>
Giovanna Mallucci, MD, PhD  
Cambridge University, UK  
$268,634

Vincent Zurawski, PhD  
Varinel Inc.  
$239,700

Peter Nelson, MD, PhD  
University of Kentucky  
$149,997

OTHER

Additional Targets

Dirk Beher, PhD  
Asceneuron SA  
$325,000

Mauro Costa-Mattioli, PhD  
Baylor College of Medicine  
$150,000

Nathalie Pochet, PhD  
Brigham & Women’s Hospital  
$135,000

Partnerships

David Knopman, MD  
National Biomedical Research Ethics Council, Inc.  
$100,000

Michael Weiner, MD  
University of California, San Francisco  
$100,000

Olga Meulenbroek, PhD  
Radboud University Medical Centre  
$380,224

Lenore Launer, PhD  
Intramural Research Program, National Institute on Aging  
$80,264

Sung Ok Yoon, PhD  
Ohio State University  
$47,397

Mauro Costa-Mattioli, PhD  
Baylor College of Medicine  
$15,000

Nathalie Pochet, PhD  
Brigham & Women’s Hospital  
$135,000

David Wholley, MA  
Foundation for the National Institutes of Health, Inc.  
$100,000

Prvention

Deborah Blacker, MD, ScD  
Harvard Medical School  
$25,000

Marek Brzezinski, MD, PhD  
University of California, San Francisco  
$300,000

Galit Wainstein, PhD  
Boston University School of Medicine  
$82,789

VASCULAR

Hyung Jin Ahn, PhD  
The Rockefeller University  
$150,000

Narayan Bhat, PhD  
Medical University of South Carolina  
$230,961

Sandra Black, MD, FRCP(C)  
Sunnybrook Research Institute, University of Toronto, Canada  
$1,442,388

Atticus Hainsworth, PhD  
St George’s, University of London, UK  
$464,992

Ihab Hajjar, MS, MD  
Emory University  
$973,777

Ling Li, DVM, PhD  
University of Minnesota  
$200,000

Raymond Scott Turner, MD, PhD  
Georgetown University  
$2,059,207 (in contract)

Neuroprotection

Neuroimaging & Biomarkers

Neuronal Energy Failure

Cognitive Enhancers

Epigenetics

Fronttemporal Degeneration

Neuro-inflammatory

Other

5%

4%

2%

11%

21%

7%

26%

14%

6%

Our Diversified Portfolio of Drug Targets in 2015

VASCULAR

Hyung Jin Ahn, PhD  
The Rockefeller University  
$150,000

Narayan Bhat, PhD  
Medical University of South Carolina  
$230,961

Sandra Black, MD, FRCP(C)  
Sunnybrook Research Institute, University of Toronto, Canada  
$1,442,388

Atticus Hainsworth, PhD  
St George’s, University of London, UK  
$464,992

Ihab Hajjar, MS, MD  
Emory University  
$973,777

Ling Li, DVM, PhD  
University of Minnesota  
$200,000

Raymond Scott Turner, MD, PhD  
Georgetown University  
$2,059,207 (in contract)

Neuroprotection

Neuroimaging & Biomarkers

Neuronal Energy Failure

Cognitive Enhancers

Epigenetics

Fronttemporal Degeneration

Neuro-inflammatory

Other

5%

4%

2%

11%

21%

7%

26%

14%

6%

Our Diversified Portfolio of Drug Targets in 2015

VASCULAR

Hyung Jin Ahn, PhD  
The Rockefeller University  
$150,000

Narayan Bhat, PhD  
Medical University of South Carolina  
$230,961

Sandra Black, MD, FRCP(C)  
Sunnybrook Research Institute, University of Toronto, Canada  
$1,442,388

Atticus Hainsworth, PhD  
St George’s, University of London, UK  
$464,992

Ihab Hajjar, MS, MD  
Emory University  
$973,777

Ling Li, DVM, PhD  
University of Minnesota  
$200,000

Raymond Scott Turner, MD, PhD  
Georgetown University  
$2,059,207 (in contract)

Neuroprotection

Neuroimaging & Biomarkers

Neuronal Energy Failure

Cognitive Enhancers

Epigenetics

Fronttemporal Degeneration

Neuro-inflammatory

Other

5%

4%

2%

11%

21%

7%

26%

14%

6%
OUR SUPPORTERS

We are moving closer to finding a cure for Alzheimer’s disease thanks to your generosity. Many of our supporters—like Nancy Goodes and Christopher Johnson—have had a loved one affected by Alzheimer’s or a related dementia and know firsthand how badly treatments are needed. We thank them and all of you for your unwavering dedication to our mission.

“When my husband, Mel, was diagnosed with Alzheimer’s disease there was no deliberation about the best organization to work with to find a cure. As the former CEO of Warner-Lambert, Mel knows a lot about developing drugs, and he knows that the ADDF is unrivaled in its scientific expertise and approach to defeating Alzheimer’s.

Throughout his career, Mel has been relentless in his search for drugs that improve people’s lives. The ADDF is equally relentless in its mission to support the best science in the fight against Alzheimer’s.

Mel and I established the Melvin R. Goodes Prize for Excellence in Alzheimer’s Drug Discovery to recognize outstanding scientists in the search for a cure. It is an honor to have our name linked to the ADDF in this way.”

NANCY GOODES
ADDF Board of Governors

“When Alzheimer’s touched my family I felt compelled to find a way to rid the world of this disease. In the ADDF, I discovered a vibrant community of scientists, volunteers, and professionals who understand and share my urgency to solve Alzheimer’s. They know on both a scientific and human level that something can and must be done as quickly as possible, and their devotion is evident in everything they do.

The ADDF is so much more than just an Alzheimer’s research nonprofit. It is a community of people devoted to this fight. From the founders who make sure that every dollar raised goes directly to drug discovery to the supporters with personal stories and motivations that mirror my own—everyone at the ADDF shares the unflappable belief that we can and will end Alzheimer’s.

If there’s one good thing that has come out of my family having to deal with my father’s Alzheimer’s, it’s that we’ve become closer than we ever were. I’m fortunate to have found an organization that can bring families like mine together with others, and harness our collective desire to make sure that future generations won’t have to suffer the effects of this disease.”

CHRISTOPHER JOHNSON
ADDF Board of Overseers
CELEBRATING PROGRESS

In 2015, the ADDF recognized leaders in Alzheimer's philanthropy and research while celebrating the progress we've made in developing effective treatments for this disease. We thank everyone who came together and supported our events and look forward to seeing you next year.
THANK YOU

We are deeply grateful to all those who supported our work in 2015. Your generosity gives us hope for a future without Alzheimer's disease.

OVER $1,000,000
Anonymous (2)
The Lauder Foundation – Leonard & Judy Lauder Fund
Jo Carole and Ronald S. Lauder

$100,000 – $999,999
Alzheimer's Society of UK
The Association for Frontotemporal Degeneration
Judy and Ron Baron, Baron Capital Foundation
Ray and Dagmar Dolby Family Fund
Nancy and Melvin R. Goodes
Frances and Nathan Kirsh
Robert A. and Renée E. Belfer Family Foundation
Liz and Randal B. Sandler Sotheby’s
Thomas C. Mason Charitable Remainder Trust

$50,000 – $99,999
A.P. Kirby, Jr. Foundation, Inc.
ALS Biopharma, LLC
Helen and Robert J. Appel

$25,000 – $49,999
Anonymous
Beacon Trust
Biogen
Bloomberg L.P.
Carol Seabrook Boulanger
Rose Marie Bravo and William Jackey
BrightFocus Foundation
Caryn J. Clayman
Annette and Mitchell D. Eichen
EY
Harrington Discovery Institute / Biomotiv
Laura and Gary Lauder
Bonnie Englebardt Lautenberg
Susan Lloyd
Beatrice Liu and Philip H. Lovett
Macy’s and Bloomingdale’s
Georgia Garinois Melenikiotou
Shelah and Marc Moller
Newmark Grubb Knight Frank
The Northern Trust Company
Nucor Construction
Pfizer Inc.
Sharon and Robert Prince
Quest Diagnostics
The Ralph and Ricky Lauren Family Foundation, Inc.
Louise and Leonard Riggio
Lois Robbins and Andrew Zaro
Samuel I. Newhouse Foundation
Janet Prindle Seidler
Trish and Steven J. Shapiro
Thomas W. Smith
Susan and Peter J. Solomon
Staples Advantage
Jennifer and Mark Stysslinger
Teauman and Grace Fuite Foundation
Ann and Andrew Tisch
Tishman Speyer Properties, LP

$10,000 – $24,999
Anonymous (2)
Pennie and Gary Abramson
Toby and Ronald A. Altman
Jennifer and Claude Amadeo
Aon Foundation
Placido Arango
Claire and Daniel S. Bernstein
William K. Bowes
Amy and Gordon Caplan
Linda and Arthur L. Carter
Gary D. Cohn
Meryl Comer
Valerie and Charles M. Diker
B. Faye Doolittle
Anne B. and Joel S. Ehrenkranz
Cheryl Strauss Einhorn and David M. Einhorn
Emanuel J. Friedman Philanthropies
Sandi and Andrew Farkas
Betty and David C. Farrell
First Republic Bank
Barbara and Richard I. Furman
James L. Haskel
Susan and Roger Hertog
Joanna Horgan
Howard Gilman Foundation
Amber and Mitchell Kanef
Barbara and Donald G. Tober
Carol and Michael Weisman
Wendy Wilshin and Ronald Dickerman
Paula Zahn
Eleanora R. Kennedy
Nancy Kestenbaum and David Klafter, Esq.
David H. Komansky
Kate and John Krebsbiel
William P. Lauder
Carole Cooper and Richard Leibner
Serena and John Liew
Margaret and Daniel S. Loeb
Sandra and Bernard Magnussen
Maureen A. and Alan J. Maguire
JoAnn and John Mason
William E. Mayer
Carly S. and John McCaffrey
Merck Research Laboratories
Pamela J. Newman
Otsuka
Cobey and Robert Rapaport
Martine Reardon
Margaret Rice
Denise Rich
Roche Pharmaceutical Research and Early Development
Sharon and Daniel Roitman
Hilary and Wilbur L. Ross, Jr.
Janet C. Ross
Ophelia and William C. Rudin
Sharon T. Sager and J. Loring Swasey
Hadley and John H. Scully
Signum Biosciences, Inc.
Larry Silverstein
SkyBridge Capital
Takeda
Mary Rose Taylor
Toyota of Palo Alto
Lorraine Wallace
Wittmann Building Corp
Linda Zambelli, US Trust, Bank of America Private Wealth Management

$5,000 – $9,999
Anonymous (2)
AC Immune
Bret Ackerman
Sonia and Warren Adler
Shelley and Robert Banks Belk, Inc.
Alicia and William Blake
Faith Bobrow
Evelyn and Lawrence N. Brandt
Estrellita and Daniel Brodsky
Bobbi Brown and Steven Plofker
Bettina Bryant
Children’s Tumor Foundation
Michael T. Cohen
Mary Davidson
John D. Demsey
Douglas DiPasquale
Dolby Family Ventures
Father’s Day/Mother’s Day Council, Inc.
The Fribourg Family
Ann B. and Thomas L. Friedman
David Gerson
Carol Brown Goldberg and Hank Goldberg
Andrea and James A. Gordon
Sara Moss and Michael Gould
Janet and Allan Green, PhD, MD, JD
Glenda Greenwald
Audrey and Martin D. Gruss
H. van Ameringen Foundation
Nona Heaslip
Maria Hummer-Tuttle and Bob Tuttle
Lynette and Richard Jaffe
Deborah and Peter Krulwich
Linda G. and Steven Levy
Susan and Thomas H. Lowder
Carol and Earle I. Mack
Holly and John Madigan
The Marc Haas Foundation, Mr. and Mrs. Stanley Shuman
Susan and Morris Mark
The Mount Sinai Medical Center
Nuveen Investments
Terri and Steven H. Oram
Susan and Alan J. Patricof
PepsiCo Foundation
Pfizer CTI
Pilar Crespi Robert and Stephen Robert
Susan and Jack Rudin
Patricia Bennett Sagon
Joan and George W. Schiele
June and Paul C. Schorr III
The Sheldon H. Solow Foundation
Karen and Spencer G. Smul
Debbie and Craig R. Stapleton
Jeanette Sarkisian Wagner
Sarah and John F. Walsh

$1,000 – $4,999
Anonymous (2)
Katherine and Paul S. Adler
Alliance for Aging Research
Tina Alster, MD
Jean M. and Timothy J. Alvino
Ann and Steven Ames
Gloria and Kim C. Anderson
Roger Anderson
Richard Aneser
Judy and John M. Angelo
Linda and Robert Aquilina
Ariel Investments, LLC
Richard Attias
Martin Auerbach
John Avery
Peter Banks

Daniel Martin Watterson
Charlotte C. Weber, Live Oak Foundation
USAgainstAlzheimer’s Network
Vradenburg Foundation, Trish and George Vradenburg
Sue Ann Weinberg
Harriet and Ronald Weintraub
Sue and Darrell Willerson
William H. Pitt Foundation, Inc.
Willkie Farr & Gallagher LLP
Deborah Miller Zabel and William D. Zabel
Irene and Carl Zelinsky
Virginia and Robert B. Zink

Alzheimer’s Drug Discovery Foundation | 2015 Annual Report
Leonard D. Litwin
Sharon Handler-Loeb and John L. Loeb
Linda and Harry Macklowe
Hildegarde Mahoney
Anne and Vincent A. Mai
Marlene and Frederic V. Malek
Deborah T. and Aaron J. Malo
Virginia Mancini
Manhattan Beer Distributors
Gene Manheim
Ann W. Marchant
Dobra and Bennett Marshall
Rodney Martin
Alison McCall and Peter Eliel
Julie Medler
Ellen and William Melvin
G. Nietouas Mestnas
Anita J.H. and Sam Michaels
Elaine and William A. Miller
Rita and Peter Heydon
Linda and Sidney Moskowitz
Anne W. and Charles Mott
Evangelos Mourelatos
Bettye Musham
Baillieu Myer
Sarah E. Nash
Johanne and Stephen Nelson
Enid Nemy
Melanie and Lawrence Nussdorf
Elizabeth Oliver-Farrow
Eileen and Leonard Palevsky
Mary Alice Pappas
Wanda Pedas
Elizabeth and Jeffrey M. Peek
Karen and Brian Perlman
Pharmatek
Kathleen R. and Michael J. Pierce
Piramal Discovery Solutions
Jacqueline L. Pletcher
Cynthia Hazen Polsky
Phebe Farrow Port
Janice Price
Principal Building Services
PsychoGenics, Inc.
QPS
Marie G. Raftery
Lori John R. Reinsberg
Clayton S. Reynolds
Karen and Lewis Rice
Stefan Richter
Orli and Zack Rinat
Molly Robb
Sheila Johnson Robbins
Robert M. & Lucille R. Levin and Marda L. Zimring Philanthropic Fund
James Rose
Lita Rosenberg
Meg and David Roth
Adam Rowe
Maxine and Stephen Sands
Frances G. Scaife and Tom McCarter
Thomas Scanlan
David T. Schiff
Phillip Schlein
Daria A. and Mitchell Schrage
Martin Schwartz
Nick Sclavos
Carole and Gordon Segal
Karen and Chris Segal
Bari D. Seiden
William and Jacqueline Shaw Family Foundation, Inc.
Finley and Patrick Shaw
Singulex, Inc.
Tina B. and Albert H. Small
Ann and Richard H. Solomon
Solvias, Inc.
Lisa and Denis Somar
Maurice Sonnenberg
Lisa B. Spikell
Bonnie K. Staffier
Sharon and Cary Stamp
Judy and Michael H. Steinhardt
Bonnie and Thomas W. Strauss
Agnes Hsu-Tang and Oscar L. Tang
Taub Institute for Research on AD and the Aging Brain
Judith and A. Alfred Taubman
Daniel Termini
Bee and Bradley R. Thayer
Judith and Michael Thoyer
David Tillson
Judy Toma
Martha Gross and Robert Tracy
Tracey T. and Richard Travis
Alexandra C. Trower and Jon Lindsey
United Way Ottawa
Eunice C. Valdivia
Valley Biosystems
Lauren and John Veronis
Viking Global Investors LP
Marilyn Wallach
Sandra and Stanford S. Warshawsky
Martin Washington
Rosemary Fine Weaver
Virginia A. Weil
Jane Greenwald and Lawrence A. Wein
Wheels, Inc.
Joel Whidden
Carolyn and Malcolm H. Wiener
The Honorable and Dr. Marcus Williams
Elaine and James Wolfensohn
Helena Wong
Janice Worth
Wyndham Hotel Group

$500 – $999
Anonymous
Patty Abramson and Les Silverman
Lise Adkins
Theresa Almos, PhD
Carolyn S. Alper
Peter J. Anderson
Ellen and Rick Arnold
Bonnie and Arthur Ashman
Marion Bachrach and Jonathan Siegfried
Margot Bakker, PhD
Andrew Baron
John W. Beckley
Tracy Bernstein

Alzheimer’s Drug Discovery Foundation | 2015 Annual Report
Fabienne and Patrick Bousquet-Chavanne
The Brooks Foundation
Bruce A. Gimbel Foundation
Nancy and Alan Bubes
Tauseef Butt, PhD
Suzanna Charnas
Diane and Keith Chasin
Qian Chen, PhD
Anne-Marie Chollet
Judith G. Churchill
Vicki Clements, EdD
John J. Connolly, EdD
Linda V. Courie
Wyatt Crowell
Dattner Architects
Kyle Delaney
Carole and Philippe Delouvrier
Michael Devous, MD
Paul Doran
Elizabeth Dubin
Bonnie and Kenneth Feld
Diana Feldman
Bill Fielding
Anne Ford
Debbie Forrest
Joseph Foss, MD
Harriet and Joe Foster
Rachel Franzblau
Julie Frearson
Anita Friedman
Barbara J. and Ronald M. George
William T. Georgis
Miriam and Michael Gervis
Diana and Harrison J. Goldin
Jill and Robert Granader
Phyllis Grann
Jan and Ronald Greenberg
Sylvia Greenberg
Julia and Warren Gregory
Cheryl Gretzula
Mary Haft
Jacqueline Harman
Ellen R. Harris
John Hart
Janet Hector
Amy and Robert Heller
Arlene and Milton Herson
Robert M. Higdon
Barbara and Gerald Hines
George Hoey
Rosalind G. Jacobs
Daniel Janiak, PhD
Linda and Morton Janklow
Peggy and Scott Kalb
Jayne T. Keith
Anne and John Kelsey
Kiyokai Kobayashi, PhD
John Kossow
Elizabeth S. Kujawski and Tom Zoufaly
Eileen and Richard W. Kunes
Margo Langenberg
Paul Lenoci
Margaret and Terry Lenzner
Pierre Lestage
Julie and Jerrold G. Levy
Lawrence Luebcke
Edoardo Marcora, PhD
Richard Margolin, MD
Debbie and Troy W. Maschmeyer, Jr.
Takeshi Matsuya, PhD
Katherine Mayer
Lyn and Mark D. McFadden
Susan and Robert McLean
Ray Meeks
Benoit Melchior, PhD
Jennifer and Brad J. Melvin
Mariann Mihalidis
Susan and Mark Mintun, MD
Triana M. and James Moe
Thomas Moeller, PhD
Robert Morrison
Enid and Lester S. Morse, Jr.
Clare Murray, PhD
Rick Mylin
Wener Neidhart, PhD
Judith E. Neisser
Ann K. and William Albert Nitze
Toru Noguchi, PhD
Bonnie Osher
Evangelina and Theodore Pedas
Ernest and Duane Pepples
Marina Peredo
Louise and Paul Pesale
Laura H. and John Pomerantz
Pamela Reimers
Marina and Keith Richey
Janie Riddle
Anne Rogers
Amy and Frank Romeo
James J. Ruddy
Stephen I. Sadove
Jo Sakurada, PhD
Stacey Samet
Leslie and Richard L. Sandler
Maria and Greg Savettiere
Ernest Scheyder II
Steven Schroko
Barbara Schwartz
Miyako and Edmondo Schwartz
Paul Scordia
Laura and Gerald Shanley
The Silver Fund
Dusanka Skundric, MD, PhD
Constance and Stephen Spahn
Lauren and Jay Springer
Jeffrey Sprouse, PhD
Micheale Stanton
Leslye and Fred Sugar
William Sweeney
Vicki and Harold Tananbaum
Russell Thomas, PhD
Kari Tiedemann
Yuriko Toriumi
Lee Traub
Sahba Vaziri and Ali Reza
Suzy and Sadek Wahba
Mary and Kenneth H. Walker, FAIA
Allison and Lou Wallach
Feng Wang, PhD
Richard Watson, MD
Molly and Peter Weinberger
$250 – $499
Anonymous in memory of
Mr. Jacques Boulanger
Maureen Anne Abraham
Allstate
Susie Anderson
Steven Bailey, PhD
Marcie Bane
Bank of America Matching Gift Program
Denise Barbut
Crystal Barganza
Melissa Bauer
George Bean
Vince Belitsos
Susan and Joel Bell
Daniel Benjamin, PhD
Mary Berner and Sally Whaling
Narayan R. Bhat
Huntington T. Block
Andrew M. Blum
Emily Braun
Dale Bredesen, MD
Brian Brookover
Susan Brown
Karen E. Burke and Mr. Peter J. Goulandris
Mary Lynn Cabrera
Dongming Cai, MD, PhD
Hilary P. and Joseph A. Califano
Jesus Campagna
Wendy N. Carduner
Isabel Carreras, PhD
Susan and Paul Cavanaugh
CBIZ Risk & Advisory Services Group
Jackie Chalkley
Hassan Charara
Mary Cheaney, PA, CPA
Robyn and William M. Collins
Kyle Corigliano
Karen and David Cornman
Kevin K. Cornell
Lauren Cranston
Hillary Cullen
Ashley and Alan Dabbiere
Sandi A. Davidson
Tracy Davidson
Sara E. and Philip J. Davis
Barbara and Ronald Demczak
Ron Demuth
Kristen Denny
Nazneen Dewji, PhD
Matthew Dicker
Jill Lesser and Jonathan Diesenhau
Frances Dinkelspiel
Jamie Dorros
Silvia and Peter Dreyfuss
Mickey Djigaj-Djordjevic, PhD
Keith Durante
Gustavo Dziewczapolski, PhD
Steven English
Deborah Epstein
Patricia and John Esposito
Milton Esterow
Kathleen Farrell
Larissa Felt
Margaret and Floyd Flake
Andrew Frackman
Jennifer L. Franklin and Scott Hall
Timothy Gallagher, PhD
Ivana and Emile H. Ghattas
Cynthia H. and Michael J. Gibbons
Darby E. and J. Montgomery Gingery
Nicole Giroux
Goldman Sachs & Co. Matching Gifts Program
Marjorie Reed Gordon
Sheila and Martin Grossman
Deborah Gurner
Susan and John H. Gutfriend
Jennifer Haber
Lori and Khaled T. Haram
Dana and Howard J. Harrison
Heidi Hatfield
Susan C. and Robert M. Hayes
Lesley Heller
Sandi Hoffman
Gloria Honeck
Berna Huebner
Sloane Hurst
Ira M. Resnick Foundation, Inc.
Phyllis Isaacs
Catherine Jackson
David Jacobson
Amy and David Jaffe
Peter Jeffries
Varghese John, PhD
Alex Joseph
Jand and Ken Kalina
Kalev Kask, PhD
Dolores Kay
Kay Kendall
Justin Kidwell
YooRi Kim
Eileen and John Kim
Mitchel Kling, MD
Carol and B. Erik Knudsen
Paul Koulogeorge
Christine Lai
Andrea LeBlanc, PhD
Danielle Lee
Arthur Lee
Jennifer Levin
HongHua Li, PhD
Christine M. Lin
Joyce F. Luchtenberg
Patricia and Gary Lunka
Adam Mahr
Alexandra Main
Carolyn B. Maloney
Nancy and Steven Manket
Robin Mansukhani
Elaine A. Marstad
Kennedy Matsagas
Owen McGettrick
Wendy and Daniel McGrath
Laura McIntire
Janie McMahon
Charles McNulty
Michael Mercurio
Linda E. Meyer
Beverly Michel
Kimberly Michienzi
Thomas Middleton
Anne and Philip B. Miller
Liat Mintz
Felix A. Miranda, Jr.
Donald Morrissey
Carly and John Murphy
Aaron Nagano
Mike Nerenberg, MD
Rachel and Larry Norton
Sybille Novack
Steven Padgett
Vita Pagnani
Kathleen Parsons
Jack Pasini
Mary Ann Pelleymounter, PhD
Joe Perpich
Suzana Petanceska
Pfizer Foundation Matching Gifts Program
Annette Polan
Monika Polewski
Lynette H. Posorske, MD
Gigi Pritzker and Michael Pucker
Jay Radin
Rebecca B. Richardson
Liz Robbins and Doug Johnson
Robert Derector Associates
Manuel Roig-Franzia
Anne Rorimer
Eleanor T. Rosenfeld
Stacey Rosenthal
Joel Ross
Ifet Sakiyan, PhD
James Sampson
Thomas E. Sandell
Rosita Sarnoff
Susan and Gerald S. Savitsky
Lorraine Schapiro
Kristen Scheyder
John Seabrook
Nancy Seltzer
The Selz Foundation
Rick Shin, PhD
Deborah Sigmund
Marla and Thomas Sinchak
Lee Slattery
Andre Spearman
Patricia Spilman
Margaret L. Stewart
Grace Stutzmans, PhD
Mark Suto, PhD
Julie Swartz
Kinga Szigeti, MD, PhD
Jami Taff
Man Tang, PhD
Robin Taub and Michael Pfeifer
Shawn and Ray H. Taylor
Jeni and Seth Therrien
Paul Trippier, PhD
Molly Wagster
Abbas Walji, PhD
Marcia and Robert N. Waxman
Jill and Jon Weiner
Anita Weinstein
Tina West, MD
Lisa Whisenhunt
Frances Wiener
Stephanie Witowski
Mary Woolley
Barbara B. Wright
Crystal Wright
Sissy Yates
Keqiang Ye, PhD
Leigh Zawel, PhD
Mina Zion

*Multi-year pledge

**IN-KIND GIFTS**

Akris
Tina Alster, MD
Amaryllis, Inc.
American Airlines
Anya Hindmarch
ArtMuse

Assael Inc.
Balance, Your Pilates, Yoga & Gyrotonic Studio
Rochelle Bloom
Brooklyn Running Company
Bumble and bumble.
Café Milano
Colliers International NY LLC
Nancy Corzine
dell’ anima
Dempsey & Carroll
Design Cuisine
Boulud Sud
Feld Entertainment
Fiola Mare
Geoffrey Beene Foundation
Alzheimer’s Initiative
Gillies Coffee Company,
Brooklyn New York
GODIVA Chocolatier
Holman Ranch Vineyards & Winery
KARMA by Erwin Gomez
Elise and Marc Lefkowitz
Oscar Heyman Brothers
The Phillips Collection
Prestige Beverage Group
Rasika West End
The Ritz-Carlton, Washington, DC
Sharon T. Sager and J. Loring Swasey
Salamander Resort & Spa
The St. Regis New York
Stoli Group USA
Teuscher Chocolates of Switzerland
In 2015, many generous gifts were made to the Alzheimer's Drug Discovery Foundation in honor of friends and loved ones.

Nancy and Dan Abramson
Harry Albert
Sandra Annex
Ruth Bachrach
Seth Birnbaum
Rochelle Bloom
William Boulais
Arlene A. Brown
Bea Burke
Dave Cochrane
Robert L. Cohen
Meryl Comer
Marti Dinerstein
Agnes Farrell
Howard Fillit, MD
Josephine Giordano
Nancy and Mel Goodes
Suzanne Grimes and David Jeffries
Pauline Harris
Janet Hector

Nancy Horner
David Humayun
Fern Jaffe
Allison Johnson
Kiera and Christopher Johnson
Carolyn Jones
Deborah Krulewitch
Estée Lauder
Evelyn Lauder
Judy and Leonard A. Lauder
Ronald S. Lauder
Elise and Marc Lefkowitz
Suzanne Lloyd
Margaret and Dan Loeb
Michael Mayone
Louis McDonough
Herbert Milstein
Marc Moller
Patrick Pean
Lenore Pletcher
Laura Prozes
Dorothy Reed
Phoebe Rice
Burton Rose
Jacqui Rosshandler and Matt Dicker
Selma Rowe
Irene Rucicot
Janice Rubart
Liz and Randal Sandler
Maggie Sandler
Richard Sander

In Memory
We remember all those who succumbed to Alzheimer’s by continuing to fight for a cure.

Sharon Anderson
Alvin Bernstein
Bernard Bloom
Jean Boilard
Molly Cohen
Jerome Connolly
Antonio Coppola
Bonnie Dollahite
Joe Figlmiller
Sylvia Friedman
Franco Grieco
Rose Heisinger
Michael Hollander
Diane M. Johnson
William Lee Johnson
Gerald Kaufman
Marvin Kay
Franklin W. Krum
Frances Lewis
June Manheim
Rick and Sherry Murray
Dorothy Nell Kilgore Gatch
Charles F. Oberle
Thelma Orenstein
Mary Patton
Louise Pavone
Muriel Percy
Walter Poschmann

Joe Proietti
Ethel Reardon
Jaime Roitman
Lois Rosenberg
Rudolph Schlobohm
Donald Schulman
Sonny Sears
Maria Elvira Sotolongo
Evelyn E. Sundberg
Helen “Sweetie” Means
Thomas L. Tiffany
Toby Wexler
BOARD OF GOVERNORS

HONORARY CHAIRMAN
Justice Sandra Day O’Connor

CO-CHAIRMEN
Leonard A. Lauder
Ronald S. Lauder

VICE CHAIRMAN
Randal Sandler

EX OFFICIO
Howard Fillit, MD

Robert J. Appel
Robert A. Belfer
Roberta Diaz Brinton, PhD
Nancy Corzine
Lanny Edelsohn, MD
Bonnie Pfeifer Evans
Melvin R. Goode*
Nancy Goode
Gary M. Lauder
Laurence C. Leeds, Jr.
Bruce McEwen, PhD
Thomas F. McWilliams
Richard Mohs, PhD
Steven Marc Paul, MD
Lady Lynn Forester de Rothschild
Alice Shure
Peter J. Solomon
Sally Susman*
Paula Zahn

*Honorary member

BOARD OF OVERSEERS

CO-CHAIRMEN
Sharon T. Sager
Randal Sandler

Carol Seabrook Boulanger
Charles Cangro
Mitchell D. Eichen, JD
Allan M. Green, MD, PhD, JD
Christopher Johnson
Bonnie Englebardt Lautenberg
Elise Gelman Lefkowitz
Philip Lovett

Emilio Matt
Julie Medler
Pamela J. Newman, PhD
Phebe Farrow Port
John H. Scully
Mary Rose Taylor
Stephen Toma
Wendy L. Wilshin
Alison Zaino
Linda S. Zambelli

STAFF

EXECUTIVE
Howard Fillit, MD

SCIENTIFIC AFFAIRS
Sara Classen
Penny Dacks, PhD
Lauren Friedman, PhD
Yuko Hara, PhD
Andrew Koemeter-Cox, PhD
Nick McKeenan
Heather Brown Moore
Diana Shineman, PhD
Dan Teng

DEVELOPMENT
Rochelle Bloom
Jessica Cavanaugh
Jennifer Iselin
Laura Morrison
Heather Paul, PhD
Sarah Toeke
Giorgio Zeolla

COMMUNICATIONS
Sumy Cho
Krishna Knabe
Jessica Levine

FINANCE & ADMINISTRATION
Diane Bartiromo
Ethan Hutchinson
Katie Mischik
Aspasia Moundros

All lists current as of May 2016.
### STATEMENT OF FINANCIAL POSITION

<table>
<thead>
<tr>
<th>ASSETS</th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>4,903,074</td>
<td>4,923,325</td>
</tr>
<tr>
<td>Investments, at fair value</td>
<td>20,649,664</td>
<td>10,809,963</td>
</tr>
<tr>
<td>Contributions receivable</td>
<td>4,962,392</td>
<td>4,059,717</td>
</tr>
<tr>
<td>Program related investments</td>
<td>536,800</td>
<td>–</td>
</tr>
<tr>
<td>Due from Institute for the Study of Aging</td>
<td>82,008</td>
<td>133,215</td>
</tr>
<tr>
<td>Other assets</td>
<td>25,366</td>
<td>26,103</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td><strong>$31,159,304</strong></td>
<td><strong>19,952,323</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LIABILITIES AND NET ASSETS</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Liabilities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts payable and accrued liabilities</td>
<td>$100,536</td>
<td>49,324</td>
</tr>
<tr>
<td>Grants payable</td>
<td>13,504,012</td>
<td>11,513,136</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>3,680</td>
<td>61,350</td>
</tr>
<tr>
<td><strong>Total liabilities</strong></td>
<td><strong>13,608,228</strong></td>
<td><strong>11,623,810</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Net assets</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Unrestricted</td>
<td>13,004,344</td>
<td>4,361,805</td>
</tr>
<tr>
<td>Temporarily restricted</td>
<td>4,546,732</td>
<td>3,966,708</td>
</tr>
<tr>
<td><strong>Total net assets</strong></td>
<td><strong>17,551,076</strong></td>
<td><strong>8,328,513</strong></td>
</tr>
</tbody>
</table>

| Total liabilities and net assets | $31,159,304 | 19,952,323 |

### STATEMENT OF ACTIVITIES

#### CHANGE IN NET ASSETS

<table>
<thead>
<tr>
<th>Support and Revenues</th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Support</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contributions and grants</td>
<td>$17,524,509</td>
<td>6,514,722</td>
</tr>
<tr>
<td>In-kind services and contributions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contributions of services from the Institute for the Study of Aging, Inc.</td>
<td>3,098,678</td>
<td>2,832,504</td>
</tr>
<tr>
<td>Contributions of advertising</td>
<td>440,200</td>
<td>–</td>
</tr>
<tr>
<td>Contributions of professional services</td>
<td>35,000</td>
<td>–</td>
</tr>
<tr>
<td>Proceeds from special events, net of direct expenses</td>
<td>3,590,294</td>
<td>2,818,092</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Revenues</th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grant Returns, net of payments</td>
<td>920,018</td>
<td>1,799,905</td>
</tr>
<tr>
<td>Conference registration fees and other income</td>
<td>335,118</td>
<td>226,173</td>
</tr>
<tr>
<td>Investment and other (loss) income</td>
<td>(18,367)</td>
<td>106,622</td>
</tr>
<tr>
<td><strong>Total support and revenues</strong></td>
<td><strong>25,925,460</strong></td>
<td><strong>14,298,018</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Expenses</th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Program services</td>
<td>14,460,393</td>
<td>10,850,140</td>
</tr>
<tr>
<td>Fundraising</td>
<td>1,772,890</td>
<td>1,236,175</td>
</tr>
<tr>
<td>Management and general</td>
<td>469,614</td>
<td>493,156</td>
</tr>
<tr>
<td><strong>Subtotal</strong></td>
<td><strong>16,702,897</strong></td>
<td><strong>12,579,471</strong></td>
</tr>
<tr>
<td>Expense for uncollected pledge</td>
<td>–</td>
<td>925,000</td>
</tr>
<tr>
<td><strong>Total expenses</strong></td>
<td><strong>16,702,897</strong></td>
<td><strong>13,504,471</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Change in net assets</th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>9,222,563</td>
<td>793,547</td>
<td></td>
</tr>
</tbody>
</table>

| Net assets, beginning of year, as reclassified | 8,328,513 | 7,534,966 |

<table>
<thead>
<tr>
<th>Net assets, end of year</th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>$17,551,076</td>
<td>8,328,513</td>
<td></td>
</tr>
</tbody>
</table>